The fact of choosing one treatment or another to address the disease will depend on several factors such as the type of tumor, the stage, the presence of genetic mutations or the existence of metastases, among others. In general terms, luminal cancer requires hormonal treatments highly protocolized, while TNBC lacks effective treatments, and has a five-year survival rate of 20-90% depending on its stage. HER2+ breast cancer presents limitations in treatment, with high toxicity of certain chemotherapeutic agents and resistance generated by the tumor cell to ant-HER2 therapies. This, together with the clinical relevance of TNBC, in the absence of an effective therapy, entails the need to explore other alternatives to address this disease: improve existing treatments or generate new drugs.

Despite of the impressive progress in biotechnologies and further understandings of the disease biology, the development of new, practical and innovative therapeutics remains an arduous, time-consuming, and expensive project, which requires collaborations from much expertise in multidisciplinary fields, including medicinal chemistry, computational chemistry, biology, drug metabolism, and clinical research.